(Q37608305)

21 August 2017

1 reference

title

Meningococcal vaccines: a neglected topic in travel medicine? (English)

1 reference

21 August 2017

main subject

meningococcal vaccine

1 reference

based on heuristic

inferred from title

author

Annelies Wilder-Smith

series ordinal

object named as

Annelies Wilder-Smith

0 references

publication date

1 October 2009

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

1343-1350

1 reference

Vaccines in travel health: from risk assessment to priorities

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Group A meningococcal carriage in travelers returning from Saudi Arabia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Adverse event reports following yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Meningococcal vaccine in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Meningococcal disease and travel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi Arabia, 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Control of epidemic group A meningococcal meningitis in Nepal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Meningococcal conjugate vaccines: efficacy and new combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Antibiotics and airline emergency medical kits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

W-135 meningococcal disease in a traveler: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Meningococcal meningitis prevention programs for college students: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

College and university compliance with a required meningococcal vaccination law.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

21 January 2018

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Human immunity to the meningococcus. II. Development of natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Prospects for vaccine prevention of meningococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Reconsideration of the use of meningococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Travel medicine--prevention based on epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Meningococcal disease: risk for international travellers and vaccine strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Dengue and yellow fever--challenges for the development and use of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Finding the real case-fatality rate of H5N1 avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.102

21 January 2018

Identifiers

DOI

10.1586/ERV.09.102

1 reference

21 August 2017

1 reference